Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Noteableon Apr 21, 2024 12:18pm
204 Views
Post# 36000185

Canada's 2024 Federal Budget increases capital gains tax

Canada's 2024 Federal Budget increases capital gains taxThe proposed capital gains tax change to 67.5% from 50%, if adopted, would come into effect on June 25, 2024.

Consequently, any Canadian company looking to be acquired would want to have the acquisition announcement to happen before that date.


As I pointed out, should an acquisition announcement be made before June 25, 2024, the current 50% capital gains tax would be grandfathered-in ... even though the closure date could be sometime after the June 25, 2024.

Otherwise, ONCY and the company's Canadian shareholders will become subject to a 67.5% capital gains tax on the acquisition of ONCY thereafter. 

If ONCY's management is prudent then an all cash acquisition of ONCY is what is necesssary, and would happen before June 25, 2024.

If they aren't, then everyone stands to loose a significant portion of their capital gains through the increase in the inclusion of the capital gains tax announced by the Canadian Federal Government, earlier this week.
<< Previous
Bullboard Posts
Next >>